Sidhaant Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 02-07-2024
- Paid Up Capital ₹ 7.65 M
as on 02-07-2024
- Company Age 20 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 22.80 Cr
as on 02-07-2024
- Satisfied Charges ₹ 11.00 Cr
as on 02-07-2024
- Revenue -24.80%
(FY 2023)
- Profit -69.49%
(FY 2023)
- Ebitda -55.67%
(FY 2023)
- Net Worth 6.99%
(FY 2023)
- Total Assets 4.57%
(FY 2023)
About Sidhaant Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 7.65 M.
The company currently has active open charges totaling ₹22.80 Cr. The company has closed loans amounting to ₹11.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sidhaant Sabharwal, Anu Nayyar, Jetender Sabharwal, and Two other members serve as directors at the Company.
- CIN/LLPIN
U51397DL2004PTC129632
- Company No.
129632
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Oct 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sidhaant Life Sciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sidhaant Sabharwal  | Additional Director | 31-May-2018 | Current |
| Anu Nayyar | Director | 31-Mar-2017 | Current |
| Jetender Sabharwal | Director | 01-Oct-2004 | Current |
| Sudarshan Sabharwal | Director | 01-Oct-2004 | Current |
| Sulabh Nayyar | Director | 15-Jun-2009 | Current |
Financial Performance of Sidhaant Life Sciences.
Sidhaant Life Sciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 24.8% decrease. The company also saw a substantial fall in profitability, with a 69.49% decrease in profit. The company's net worth moved up by a moderate rise of 6.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sidhaant Life Sciences?
In 2023, Sidhaant Life Sciences had a promoter holding of 49.67% and a public holding of 50.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Suave Med Sciences Private LimitedActive 4 years 10 monthsSidhaant Sabharwal and Sulabh Nayyar are mutual person
- Sabharwal Medicos LlpActive 4 years 6 months
Jetender Sabharwal and Sudarshan Sabharwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 25 May 2022 | ₹1.50 Cr | Open |
Axis Bank Limited Creation Date: 02 Dec 2021 | ₹8.98 M | Open |
Others Creation Date: 19 Mar 2021 | ₹2.40 Cr | Open |
How Many Employees Work at Sidhaant Life Sciences?
Sidhaant Life Sciences has a workforce of 12 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sidhaant Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sidhaant Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
